Moderna, Inc.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry`s leading mRNA technology platform. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. Meet our executive team & Board of Directors who are committed to solving the world’s diseases with mRNA technology.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical / Health Care - Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2010
About us
This Moderna page is not the appropriate place to report adverse events (side-effects ) for any products. If you are or someone you know is experiencing a side effects, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products.
History
Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.
Moderna’s name combines the words 'modified' and 'RNA', which happens to contain the word 'modern.”
Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.
New headquarters and labs open in Cambridge, Massachusetts.
Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate.
Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA
Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus.
Moderna opens its state-of-the-art clinical development site in Norwood, MA.
2019
Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial.
The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S.
2022
The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.
Our Mission
To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.